Yang Lv

Dr. Yang Lv

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2022 in Cancer Medicine
Verified
Journal Article
Open access
YLYang Lv
Yang Lv
QFQing‐Yang Feng
Qing‐Yang Feng
ZZZhi‐Yuan Zhang
Zhi‐Yuan Zhang
PZPeng Zheng
Peng Zheng
DZDe‐Xiang Zhu
De‐Xiang Zhu
GHGuo‐Dong He
Guo‐Dong He
Background: Existing studies for ferroptosis and prognosis in colorectal cancer (CRC) were limited. In this study, we aim to investigate the prognostic role of ferroptosis markers in patients with CRC and exploration of its micro‐environmental distributions.Methods: Immunohistochemical staining was performed for CRC patients’ tissue microarray. Selection and prognostic validation of markers were based on mRNA data from the cancer genome atlas (TCGA) database. Gene Set Enrichment Analysis (GSEA) was performed to indicate relative immune landmarks and hallmarks. Ferroptosis and immune contexture were examined by CIBERSORT. Survival outcomes were analyzed by Kaplan‐Meier analysis and cox analysis.Results: A panel of 42 genes was selected. Through mRNA expression difference and prognosis analysis, GPX4, NOX1 and ACSL4 were selected as candidate markers. By IHC, increased GPX4, decreased NOX1 and decreased FACL4 indicate poor prognosis and worse clinical characteristics. Ferroptosis score based on GPX4, NOX1 and ACSL4 was constructed and validated with high C‐index. Low ferroptosis score can also demonstrate the better progression free survival and better adjuvant chemotherapy (ACT) responsiveness. Moreover, tumor with low ferroptosis score tend to be infiltrated with more CD4+ T cells, CD8+ T cells and less M1 macrophage. Finally, we found that IFN‐γ was potentially the central molecule at the crossroad between ferroptosis and onco‐immune response.Conclusion: Ferroptosis plays important role on CRC tumor progression, ACT response and prognosis. Ferroptosis contributes to immune‐supportive responses and IFN‐γ was the central molecule for this process.

5 July 2020 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
YLYang Lv
Yang Lv
QFQing‐Yang Feng
Qing‐Yang Feng
YWYe Wei
Ye Wei
LRLi Ren
Li Ren
QYQingHai Ye
QingHai Ye
JXJianmin Xu
Jianmin Xu
Click on the article title to read more.

8 April 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YLYang Lv
Yang Lv
XHXu Han
Xu Han
XXXue-Feng Xu
Xue-Feng Xu
YJYuan Ji
Yuan Ji
YZYu-Hong Zhou
Yu-Hong Zhou
CHCheng Huang
Cheng Huang
Here we describe the treatments and prognosis for metachronous metastases from gastroenteropancreatic neuroendocrine tumors (GEP-NETs) after initial R0 surgical resection at a large center in China. The clinicopathological data and survival outcomes for 108 patients (median age, 54.0 years) with metachronous hepatic metastatic GEP-NETs disease who were initially treated using R0 surgical resection between August 2003 and July 2014 were analyzed using one-way comparisons, survival analysis, and a predictive nomogram. Fifty-five (50.9%) patients had pancreatic NETs and 92 (85.2%) had G2 primary tumors. For treatment of the hepatic metastases, 48 (44.4%) patients received liver-directed local treatment (metastasectomy, radiofrequency ablation, transcatheter arterial chemoembolization, etc.), 15 (13.9%) received systemic treatment (interferon, somatostatin analogs, etc.), and 45 (41.7%) received both treatments. Multivariable analyses revealed that OS was associated with hepatic tumor number (P < 0.001), treatment modality (P = 0.045), and elevated Ki-67 index between the metastatic and primary lesions (P = 0.027). The predictive nomogram C-index was 0.63. A higher Ki-67 index in metastases compared to primary tumor was an independent factor for poor prognosis. Local treatment was associated with prolonged survival of hepatic metastatic GEP-NET patients. Optimal treatment strategies based on clinicopathological characteristics should be developed.

1 March 2020 in Pancreatology
Verified
Journal Article
Closed access
MWMao Weilin
Mao Weilin
HXHan Xu
Han Xu
YLYang Lv
Yang Lv
CWChen Wenqi
Chen Wenqi
WHWang Huanyu
Wang Huanyu
XXXu Xuefeng
Xu Xuefeng

20 November 2023 in Cancer Science
Verified
Journal Article
Open access
YLYang Lv
Yang Lv
PZPeng Zheng
Peng Zheng
YMYihao Mao
Yihao Mao
YXYuqiu Xu
Yuqiu Xu
WCWenju Chang
Wenju Chang
JXJianmin Xu
Jianmin Xu
With the essential role of lipid transporting signaling in cancer‐related immunity, apolipoprotein L3 (APOL3), a member of the apolipoprotein L gene family, demonstrated significant modulation ability in immunity. However, the expression profile and critical role of APOL3 in colorectal cancer (CRC) remain unclear. This study aimed to investigate the prognostic significance of APOL3 expression and its biological predictive value in CRC. The study enrolled multiple cohorts, consisting of 911 tumor microarray specimens of CRC patients from Zhongshan Hospital, 412 transcriptional data from The Cancer Genome Atlas, and 30 single‐cell RNA sequencing (scRNA‐seq) from internal and external CRC patients. APOL3 mRNA expression was directly acquired from public datasets, and APOL3 protein expression was detected using immunohistochemistry. Finally, the associations of APOL3 expression with clinical outcomes, immune context, and genomic and ferroptotic features were analyzed. Low APOL3 expression predicted poor prognosis and inferior responsiveness to 5‐fluorouracil‐based adjuvant chemotherapy (ACT) and targeted therapy. APOL3 fosters an immune‐active microenvironment characterized by the promotion of ferroptosis, downregulation of macrophages, and upregulation of CD8+ T cell infiltration. Moreover, the expression of APOL3 in CD8+ T cells is intrinsically linked to ferroptosis and immune activation in CRC. In summary, APOL3 serves as an independent prognosticator and predictive biomarker for immunogenic ferroptosis, ACT, and targeted therapy in CRC. Furthermore, the APOL3 signaling activator could be a novel agent alone or in combination with current therapeutic strategies for CRC.

1 July 2019 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
YLYang Lv
Yang Lv
QFQing-Yang Feng
Qing-Yang Feng
SLSong-Bin Lin
Song-Bin Lin
YMYi-Hao Mao
Yi-Hao Mao
YXYu-Qiu Xu
Yu-Qiu Xu
JXJianmin Xu
Jianmin Xu
Aim: Lymph node ratio (LNR) seems to be more precise than classic N stage in classifying cancer stage. Thus, we aim to construct a modified classification system based on LNR for colon cancer without distant metastasis. Methods: This study enrolled two independent cohorts of patients. The primary cohort enrolled 2,152 patients from 2008 to 2013 in Zhongshan Hospital, Fudan University. The validation cohort consisted of 77,406 patients from the Surveillance, Epidemiology, and End Results (SEER) registry from 2004 to 2014. The inclusion criteria were: pathologically confirmed colon cancer, and American Joint Committee on Cancer (AJCC) stage I/II/III. The exclusion criteria included: incomplete follow-up information, rectal cancer, and multiple primary sites. The prognostic value of LNR for overall survival was evaluated. The cutoff value of LNR was determined by the X-tile. Predictive performance of modified classification was determined by the concordance index. Results: After analysis, 0.05 and 0.50 were determined as the best threshold values of LNR. A value of 0.50 was reclassified as the mN0, mN1 and mN2 stage. A modified classification based on mN0, mN1, and mN2 was further constructed for stage I/II/III colon cancer. C-index of the modified classification was statistically more precise than AJCC classification (0.687 versus 0.605, P<0.001). The same results can also be determined in the validation cohort (0.715 versus 0.640, P<0.001). Furthermore, a prognostic nomogram including independent factors was constructed. The constructed nomogram showed good performance according to the calibration curve. Conclusion: The clinical value of LNR level was preferable to classic N stage in colon cancer patients. Our proposed classification based on LNR and AJCC T category can effectively differentiate patients with varied survival outcomes.